Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary shares, no par value per share
-
Shares outstanding
-
491,982,609
-
Total 13F shares
-
367,379
-
Share change
-
-25,306
-
Total reported value
-
$606,135
-
Price per share
-
$1.65
-
Number of holders
-
14
-
Value change
-
-$247,038
-
Number of buys
-
9
-
Number of sells
-
5
Institutional Holders of Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) as of Q4 2025
As of 31 Dec 2025,
Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
367,379 shares.
The largest 10 holders included
CITADEL ADVISORS LLC, ADAR1 Capital Management, LLC, Ikarian Capital, LLC, KESTRA PRIVATE WEALTH SERVICES, LLC, XTX Topco Ltd, RHUMBLINE ADVISERS, JANE STREET GROUP, LLC, Virtu Financial LLC, BNP PARIBAS FINANCIAL MARKETS, and MORGAN STANLEY.
This page lists
14
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.